Objective: Depression risk increases during the menopausal transition (MT) and initial postmenopausal yearsboth times of significant fluctuations of estrogen. Research to date provides limited support for the hypothesis that estrogen fluctuations play a role in the greater susceptibility to midlife depression. Importantly, not all women report depressive symptoms during the MT, and recent reports suggest that duration of exposure to estradiol throughout the adult years may also play a role in vulnerability to depression. This study examines patterns of estrogen exposure during the reproductive years and risk of depression during the MT and early postmenopausal years.
T he menopausal transition (MT), [1] [2] [3] [4] and early postmenopausal [5] [6] [7] years confer an increased risk of major depression and depressive symptoms. These years around the final menstrual period (FMP) are characterized by fluctuating and unpredictable reproductive hormone concentrations, particularly estrogens. 8 Estradiol, the principal estrogen, modulates the synthesis, availability, and metabolism of serotonin, 9 a key neurotransmitter in depression. Thus, reproductive hormones are often considered to be involved in the susceptibility to depression, especially during periods of alterations in ovarian function such as postpartum and the MT. Nonetheless, given that fluctuations of estradiol during the MT are universal, it is unclear why only some women experience an onset of depressive symptoms during the transition. Furthermore, research to date provides limited support for the hypothesis that wide fluctuations in estrogen levels may render women susceptible to depression. Importantly, recent reports also suggest that, perhaps, duration of exposure to estradiol throughout the adult years may contribute to a greater vulnerability to depression 2, 10 Herein, we examine the relationship between duration of estrogen exposure during the premenopausal years, from menarche to MT onset, accounting for reproductive events associated with estrogen changes as potential risk factors for the occurrence of depression during the MT and initial postmenopausal years.
Estradiol is the predominant estrogen during reproductive years both in absolute levels and estrogenic activity. During the MT and early postmenopause ( 6 years after FMP), 11 there is marked variability in estradiol levels that ultimately end in a significant decline. 8, 12, 13 In epidemiologic studies, 2 including the Study of Women's Health Across the Nation (SWAN), 6 absolute estradiol levels were not associated with concurrent levels of depressive symptoms (ie, high Center for Epidemiological Studies Depression Scale [CES-D]) scores during the MT. In contrast, some studies show that wider within-patient variations in sex hormones measured over time are associated with high CES-D scores 2, 14 and administration of exogenous estradiol to depressed [15] [16] [17] women has improved mood during the MT.
The notion that hormone fluctuations, but not absolute estradiol levels, are related to depression in the MT and that use of exogenous estrogen might mitigate depressive symptoms during this period has been the cornerstone of the ''window of vulnerability'' theory. This theory proposes that the onset or worsening of mood symptoms in perimenopausal women results from the dynamic hormonal process associated with a significant fluctuation in peripheral concentrations of estradiol. 18, 19 Indeed, increased variability of estradiol has been associated with high CES-D in the MT, 2 and withdrawal of exogenous estradiol in postmenopausal women who experienced depression during the MT resulted in onset of depressive symptoms. 20 The medical literature has begun to examine the association of estrogen exposure in the reproductive years and the development of hormonally related conditions, such as breast cancer, cognitive decline, and bone fracture, during the MT. For example, fewer full-term pregnanies 21, 22 and later menopause 23 have been associated with increased risk of breast cancer; nulliparity, and late menopause, with decreased risk of cognitive decline, 24 and more years of menstruation 25 and lactation, 26 but not parity, 26 were associated with lower postmenopausal fracture incidence. These data suggest that greater estrogen exposure could be related to both positive and negative outcomes later in life.
In relation to depression, a meta-ananlysis of 14 studies found that longer exposure to endogenous estrogens, expressed as older age at menopause (defined as FMP) and a longer reproductive period, was associated with a lower risk of reported depression in later postmenopausal life. 10 Similar findings were reported in prior studies that examined adult hormone-related factors and their relationship with risk for later life depression.
14 Specifically, later menopause age, longer duration of reproductive years, and longer OC use (>10 years) were associated with decreased odds of depression during postmenopause, 14, 27 whereas parity and age at menarche were not associated with any postmenopausal depression. 14 This study investigates lifelong estrogen exposureduration over the reproductive years-and whether it is associated with risk of depression onset in the MT itself. We examine the association of patterns of estrogen exposure during the reproductive years and risk of depression during the MT and up to 10 years postmenopause. We hypothesize that longer duration of estradiol exposure from the menarche to MT, taking into account other reproductive factors, will have a lasting influence and be associated with decreased risk for the emergence of depressive symptoms during the MT.
To address the hypotheses, we utilize data regularly collected over 10 years from women aged 42 to 52 at study entry, who are participants in SWAN-a large multisite study of menopause and aging. In addition to duration of years between menarche and MT, we evaluate several other adult hormone-related factors as potential contributors to estrogen exposure and thus to MT depression risk. Specifically, we looked at the impact of oral contraception use on hormone millieu, perhaps contributing to greater mood stablility in women and reducing the risk of depression, 28 during the MT. A greater number of pregnancies, which are characterized by high levels of estrogens, could also have an impact on depression during the MT. Conversely, lactation, which lowers estrogen levels, could potentially increase risk of depression during the MT.
METHODS

Participants
The SWAN is a longitudinal, multiethnic, multisite, community-based study of menopause among initially pre and early MT/perimenopausal women. 29 Women were recruited from 1995 to 1997. Eligibility criteria included being 42 to 52 years old, having an intact uterus and at least one ovary, not being pregnant or lactating, and in the previous three months both having at least one menstrual period and not using exongenous hormone therapy (HT). Of the 16,065 screened, 3,302 eligible women (50.7% of those eligible) enrolled in the longitudinal cohort. Each of seven sites recruited white women and women from one specified minority group (African American women in Pittsburgh, Pennsylvania; Boston, Massachusetts; Detroit, Michigan; and Chicago, Illinois; Japanese women in Los Angeles, California; Chinese women in the region of Oakland, California; and Hispanic women in Newark, New Jersey). The institutional review boards at all sites approved the study protocol and all women gave their informed consent.
Participants were premenopausal at baseline and provided data at one or more MT or postmenopausal annual follow-ups MARSH ET AL over 10 years. We excluded 1,964 women whose onset of MT/ perimenopause was not observed because they were already in early MT at baseline (n ¼ 1,540) or were using HT or had a hysterectomy and/or bilateral oophorectomy or had missed visit(s) before the first MT/postmenopausal visit without HT use (n ¼ 424 women); 17 women due to an atypically older age (!60 years) at the first MT visit or age at menarche was not recorded or was atypical (<7 or >21 years); and 15 women with no MT/postmenopausal visits. The final analytic sample totaled 1,306 women, including 15, who passed directly from premenopause to postmenopause. Overall study retention at the tenth annual visit was 78%.
Procedures
The SWAN participants were assessed at study entry (baseline) and annually with a standardized protocol including self-administered and interviewer-administered questionnaires about health, lifestyle, and psychosocial factors, and a fasting blood sample for hormone measurements. At baseline, information about past medical, pregnancy, and menstrual cycles factors were obtained.
Measures
Depressive symptoms
Depressive symptoms were assessed with the CES-D, 30 which has been validated and reliable in diverse ethnic populations. [31] [32] [33] Primary analyses used a score of at least 16 to identify potential clinical depression 34 ; a score of above 22, which has been used in SWAN, was also examined as a more stringent assessment of depression. 6 
Menopause status
At each visit, menopause status was defined based on menstrual bleeding patterns in the previous 12 months in the absence of HT, and was categorized according to classifications similar to those recommended by the World Health Organization (WHO, 1996) 35, 36 : premenopausal (no change in regularity of menstrual period); MT/perimenopausal (change in regularity to occurrence of at least one menstruation in previous 12 months); postmenopausal (no menstruation for !12 months not due to medical reasons).
8,36
Reproductive history variables
The following reproductive time invariant variables were self-reported at baseline. 37 The number and outcomes of pregnancies (''How many times have you been pregnant? Please include miscarriages, stillbirths, tubal pregnancies, abortions, and livebirths''). Only pregnancies continuing beyond the first trimester (ie, live and still birth) were counted as estradiol levels increase markedly in the second trimester to about 100 times over nonpregnant levels. 38 The number of pregnancies per woman was truncated at four or more as there were few women with more. History of lactation (''If you breastfed, for how long did you breastfeed?'') was collected for each live birth pregnancy, truncating the months of breastfeeding per live birth at 6 months and then summing the months for each pregnancy. Infants typically begin to eat solids and reduce frequency and duration of breastfeeding by or around 6 months. Prolactin inhibition of gonadotropins during lactation suppresses ovulation, and estradiol levels are typically low for the first 6 months of lactation. 39 OC use (''Have you ever taken oral birth control pills, if yes, for how long?'') was categorized as 0, less than 1 year; 1, less than 3 years, 3 to 5 years, and more than 5 years. OC potency varies by estrogen formulation taken 39 ; however, distinguishing among the multiple formulations was beyond the scope of SWAN. Nevertheless, estradiol levels are more stable and tend to be higher in OC users than in women who are naturally cycling. Age of menarche (''How old were you when your periods or menstrual cycles started?'') was recorded in years. Age at onset of the MT was defined as age at the first annual SWAN visit that was beyond premenopause. This was early MT for most participants. Consistent with previous SWAN analyses, 40 the date of the transition from premenopause to perimenopause or postmenopause was interpolated as the midpoint between the two consecutive visits. Duration of estrogen exposure was calculated as the age at MT onset minus age at menarche.
Covariates
Variables obtained at baseline include age, race/ethnicity, education, employment (work at any job in the past 2 weeks), marital status, site, height, weight, including body mass index (BMI), physical activity, smoking (current vs not), mother's age at menopause, and history of use of antidepressants, barbiturates, sleeping pills, and tranquilizers before entering SWAN. Depression during a premenopausal SWAN visit was defined as a CES-D score of at least 16 and treated as a time invariant variable in analyses of depression during her MT and initial postmenopausal years.
Time-varying variables assessed at annual visits include self-reported medication use for ''nerves or depression'' at least twice per week in the month before interview. Vasomotor symptoms (VMS) were coded as frequency of hot flashes, cold sweats, or night sweats in the previous 2 weeks. Psychosocial variables included social support, the sum of four items from the Medical Outcomes Study Social Support Survey, 41 weight (by 1-kg increments), and number of upsetting life events since previous study visit.
Statistical analysis
Baseline characteristics were compared between women ever and never observed to have elevated depressive symptoms (at both the CES-D !16 and >22 levels) during the MT or up to 10 years postmenopause, using chi-square testing for categorical variables and Wilcoxon rank-sum test for continuous variables.
The association between the interval between menarche and the MT with risk of experiencing a high depressive symptoms (CES-D !16 and >22) during the MT, was estimated using random-effects binomial logistic regression. 42 Estimated associations were presented in terms of odds ratios (ORs), exponentiating model coefficients.
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Unadjusted associations of covariates with incident CES-D at least 16 were estimated in bivariate analysis of each predictor singly. Adjusted associations were estimated from a multivariate model that included duration from menarche to MT, baseline age, ethnicity, education, site, any premenopausal depression, ever-use of antidepressants at baseline, concurrent menopause status (early MT, late MT, early postmenopause, and late postmenopause), and concurrent (time-varying) antidepressant use. Prevalence of CES-D at least 16 during the MT, from early transition through early postmenopause (6 years post-FMP) was compared with late postmenopause (>6 yrs/p FMP) 36 . This cut-off was chosen to compare a time of notable variability and unpredictability in reproductive hormones, that is, up to 6 years after the FMP in contrast to the hormonal stability in later postmenopause. 10 Presence or absence of CES-D at least 16 at a premenopausal visit was included as a covariate.
Additional candidate predictors were reproductive variables (number of months breastfeeding, number of pregnancies, and OC duration), and also VMS symptom frequency, life events, baseline height/weight/change in weight, smoker, and social support. Backward selection with a cut-off of P 0.20 or less was used for these predictors. Predictors with nonlinear associations with the outcome were categorized. Participants' data were censored at initiation of HT and at hysterectomy and/or bilateral oophorectomy. Observations in which the participant was breastfeeding or pregnant, or with missing data for the outcome and/or predictors were omitted.
To assess whether the contribution of the duration between menarche and the MT onset of depression risk in the MT/ postmenopause varied by menopause status at the time depression was observed, we tested the interaction between duration of menarche to MT and concurrent menopause status. To examine the contributions of both determinants of the interval between menarche and the MT, we repeated analyses, omitting the interval as a predictor and substituting age at menarche and age at the first MT or postmenopausal visit as separate predictors. We also calculated the Pearson's correlation time from menarche to MT onset with menarche age and age at onset of MT.
Statistical significance was set at P less than 0.05; all analyses used SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Participant characteristics
Women were observed for a mean of 5.4 (SD ¼ 3.5) visits during the MT/postmenopause. The number of years from menarche to onset of MT (age at start of MT minus age at menarche) was normally distributed with a mean of 35.6 AE SD 3.2 years (range 24.4-48.9 years). Time from menarche to MT onset was negatively associated with menarche age (Pearson's correlation coefficient ¼ À0.46, P < 0.001) and positively associated with age at onset of MT (Pearson's correlation coefficient ¼ 0.86, P < 0.001). Table 1 summarizes baseline characteristics of the study sample. Women reporting depression (CES-
of depression, less education, be prior users of antidepressants, be Hispanic, and smoke at baseline.
Univariate/unadjusted associations with risk of depression in MT or postmenopause
In unadjusted analyses (Table 2) , a longer interval between menarche and MT onset was protective against risk for high depressive symptoms (CES-D !16) in MT/postmenopause. Each additional year between menarche and MT onset was associated with a 5% lower odds of depression (OR 0.95, 95% CI 0.92-0.98). The interval from menarche to MT onset continued to be significantly associated with depression in the unadjusted model even when using a more stringent CES-D cut-off score (CES-
Associations of other hormone-related factors with the risk of CES-D at least 16 during MT/postmenopause varied. Longer duration of OC use and fewer days with VMS were protective against the emergence of depressive symptoms, whereas number of pregnancies and duration of breastfeeding were not significantly associated with incidence of MT/postmenopausal depression. None of the other hormone-related factors-number or pregnancies, duration of lactation, or OC use-was statistically significantly associated with CES-D above 22 .
Other nonhormonal factors were associated with lower risk of depressive symptoms in the MT/postmenopause, including being Chinese (vs White), reporting fewer negative life events, and having higher social support. Greater risk for depressive symptoms during MT/postmenopause was found among those of Hispanic ethnicity compared with Whites, those with a history of premenopausal depression, baseline antidepressant use, and smokers. Baseline age and weight change adjusted for height were not significantly associated with MT/postmenopausal depression.
When age at menarche and age at MT were substituted for interval between menarche and MT, the former was not significantly associated with incidence of CES-D depression (P ¼ 0.262), but age at MT was negatively related (OR 0.94, 95% CI 0.91-0.97, P < 0.001).
Multivariable analyses
In a multivariate model (Table 3) 
DISCUSSION
In this study, a longer duration of estrogen exposure from menarche to the onset of MT was protective against the incidence of high depressive symptoms (CES-D score !16 and CES-D >22) through 10 years of follow-up that included the MT and initial 10 postmenopausal years. For each additional year of estrogen exposure (time between menarche and menopause onset), the odds of experiencing depression (CES-D !16) during the MT, and postmenopause decreased by 15% (17% for CES-D>22), independent of relevant demographic, psychosocial, behavioral, and health factors including VMS. The age at MT onset was the more relevant variable (vs age of menarche) for predicting incident depression during the MT/postmenopause; this is consistent with MT onset having a stronger association with the duration of the interval between the two variables because there is less variability in age at menarche than at age at onset of MT. Contrary to our hypothesis, reproductive events including pregnancy (which increases estradiol levels) or lactation (which lowers estradiol production) were not significantly associated with risk of depression during MT/postmenopause. However, longer duration of OC use, resulting in extended exposure to higher levels of estrogen and decreased exposure to natural and endogenous hormone fluctuations (as most OCS mitigate the exposure to cyclic changes in the hormone milieu), was protective against risk of depressive symptoms during MT and beyond. We found independent predictors of depression in midlife women to be similar to those previously reported, including VMS, ethnicity, stressful life events, prior depression, less education, use of antidepressants, 6 and weight change. 6, 43 Social support reduced depression risk. 44 Estradiol modulates the activity of many systems implicated in the pathogenesis of depression: regulation of neurotransmitter synthesis and metabolism, hypothalamic pituitary adrenal axis activation, neuroplasticity (including regulation of brain-derived neurotrophic factor), epigenesis, and immune system activation. 45 Our results suggest that the longer exposure to menstrually regulated estradiol variations, and also relatively steady oral contraceptive hormonal levels during the reproductive years could translate into a lasting effect on the modulation (synthesis, availability) of monoamines, such as serotonin, that are known to affect mood. Polymorphisms in genes related to estrogen synthesis and metabolism have been associated with higher risk for depressive symptoms, 46 and disturbances in the hormonal milieu due to gene-related changes in estrogen synthesis and/or metabolism may be related to depression due to downstream effects on dysregulated monoamines. 18 These indicate a possible genetic mechanism behind the risk of menopausal depression association with lifelong estradiol exposure. Another genetic explanation could include the FMR1 gene and its role in the development of neurodegenerative disorders; this gene has been associated both with risk of depression and early age of menopause. 47 Consistent with this finding are the results from The Harvard Study of Moods and Cycles that reported major depression was associated with early decline in ovarian function. 48 They 
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also found that several factors associated with early menopause could also be associated with depression and thus could be considered confounders. 49 For example, smoking is more prevalent in people suffering from depression 50 and is also associated with an earlier onset of menopause. 51, 52 Likewise, obesity is associated with depression, 53 and with a greater rate of anovulatory than ovulatory cycles in women undergoing the MT. 54, 55 This study adjusted for both smoking and BMI and our results remained significant.
History of depression has often, 49 but not always, 56 been associated with risk of early MT, possibly by disrupting hypothalamic pituitary ovarian function. 57, 58 We previously found that a history of major depressive disorder was associated with risk for depression during the MT. 59 Although this study did not have full diagnostic criteria on major depressive episode history, it did adjust for history of antidepressant use, which is a reasonable indicator of past depressive episodes. Additionally, variables associated with current stress such as upsetting life events (increased stress) and social support (decreased stress) were adjusted for. Finally, this study also adjusted for high depressive symptoms experienced by women in SWAN in their late reproductive years, but before entering the MT. Our findings of a longer duration of reproductive life being associated with a lower risk of depression during the MT remained significant through all above adjustments.
OCs have been associated with a later age at menopause, 60 and later age at MT onset has been found to be associated with a shorter MT. 61 If a shorter MT duration is itself associated with lower risk of depression during the MT and first years postmenopause, then this might help explain why age at MT onset, but not age at menarche, is related to incident depression found here.
Limitations of this study include the use of depressive symptoms, rather than categorical diagnosis of clinical depression. History of reproductive variables was assessed by self-report and retrospective recall, which is subject to recall biases or other inaccuracies. Given the data point of longest OC exposure was only above 5 years, this might underestimate the reduced risk of depression associated with OC use. Whereas the use of first perimenopausal visit as an indicator of MT onset is a soft indicator (as it is difficult to pinpoint the actual start of the MT), this increased variability would bias the estimated associations towards the null, and thus lead to a potential underestimation of the association of duration of estrogen exposure with menopausal depression.
Noteworthy strengths include a large sample with data on reproductive history, up to 10 years of prospective annual follow-up data on onset of the menopausal transition, and adjustment for multiple relevant risk factors for depression, many of which are time-varying.
CONCLUSIONS
The relative contribution of estrogen to the risk of developing depression during MT and postmenopause has long been debated. The current study provides important new evidence that reproductive events and estrogen exposure might be setting the stage premenopausally for the risk of clinically significant depressive symptoms during the MT and beyond. Differences in duration of estradiol exposure and moderators of the patterns of exposure during the reproductive years may inform future research on disentangling the inter-relationships between depressive symptoms and hormone dynamics, and aid in identifying women who are at increased risk of depression during the MT. They warrant futher investigation on the putative mechanistic factors. If further corroborated, these findings may also have implications for the extent to which variations in reproductive hormone exposure during reproductive years might subsequently alter the risk for depression later in life.
